Pharmafile Logo

News and Press Releases

NICE recommends WINREVAIR (Sotatercept) as a treatment option for adult patients in England and Wales with pulmonary arterial hypertension (PAH)

Sotatercept is indicated for use in combination with other pulmonary arterial hypertension (PAH) therapies, for the treatment of PAH in adult patients with WHO Functional Class (FC) II to III,...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: May 14, 2026

Merck
IECustomerrelations@merckgroup.com
1 rue Jacques Monod, Site Montesquieu, 33650 Martillac, France

BioMed X Institute and Merck Successfully Complete Extrachromosomal DNA in Cancer Research Project

The research of BioMed X team EDC - Extrachromosomal DNA in Cancer - has uncovered critical insights into the mechanisms driving extrachromosomal DNA (ecDNA) formation and maintenance, offering potential avenues for...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: February 6, 2025

BioMed X
info@bio.mx
BioMed X GmbH Im Neuenheimer Feld 515 69120 Heidelberg

Merck launches first-to-market, cyber-physical trust platform to tackle issues of product safety and counterfeiting

M-Trust™ is a secure cyber-physical trust platform that enables the creation of digital twins for enhanced product quality and authenticity assurances  This cutting-edge new technology is being unveiled at CES...

Category: Biotechnology, Logistics, Other, Pharmaceutical
Posted: January 7, 2025

Merck
IECustomerrelations@merckgroup.com
1 rue Jacques Monod, Site Montesquieu, 33650 Martillac, France

Merck Receives European Commission Approval for WINREVAIR™ (sotatercept) in Combination With Other Pulmonary Arterial Hypertension (PAH) Therapies, for the Treatment of PAH in Adult Patients With Functional Class II-III

26 August, 2024 – New Jersey, US – Merck, known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved WINREVAIR™ (sotatercept), in...

Category: Pharmaceutical
Posted: August 28, 2024

Merck
IECustomerrelations@merckgroup.com
1 rue Jacques Monod, Site Montesquieu, 33650 Martillac, France

Concr launches trial using digital twins for outcome prediction in breast cancer

10 July 2024, London United Kingdom – Concr announces that first patients have been recruited to the VISION trial, an observational clinical study evaluating Concr’s therapeutic response predictive algorithm defining...

Category: Biotechnology
Posted: July 10, 2024

Concr
info@concr.co
11 Milbrook, Esher, KT10 9EJ, UK

New Phesi proof of concept demonstrates potential of AI-powered digital twins to replace external control arms in clinical trials

Study published in Bone Marrow Transplantation uses real-world clinical data to create virtual digital twin cohorts instead of placebo and standard-of-care comparator arms 20 June 2024 -- Massachusetts, US --...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: June 20, 2024

Phesi
info@phesi.com
East Lyme, Connecticut, US

MSD’s WELIREG▼(belzutifan) made available for the treatment of eligible adults with von Hippel-Lindau (VHL) disease in Scotland

Scotland is the first European country to accept belzutifan as a treatment for adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL-associated renal cell carcinoma (RCC), central...

Category: Pharmaceutical
Posted: October 9, 2023

Merck
IECustomerrelations@merckgroup.com
1 rue Jacques Monod, Site Montesquieu, 33650 Martillac, France